Last update June 14, 2022
Very Low Risk
Olanzapine is an second-generation atypical antipsychotic, antimanic, and mood stabilizer used for the treatment of schizophrenia and moderate to severe mania associated with bipolar disorder, and in combination with fluoxetine for the treatment of the depressive phase of bipolar disorder and treatment-resistant unipolar depression. Oral administration once daily. Long-acting intramuscular administration every 2 to 4 weeks.
It is excreted in breast milk in clinically non-significant amount (Manouilenko 2018, Aydin 2015, Stiegler 2014, Whitworth 2010, Lutz 2008, Ambresin 2004, Gardiner 2003, Croke 2002), without problems observed in infants whose mothers were receiving this treatment, whether on psychomotor development, speech improvement and weight gaining. (Uguz 2015, Grover 2015, Stiegler 2014, Gilad2011, Whitworth 2010, Lutz 2008, Gardiner 2003, Friedman 2003, Croke 2002, Kirchheiner 2000)
Drug plasma levels in these infants were undetectable or very low. (Manouilenko 2018, Stiegler 2014, Whitworth 2010, Lutz 2008, Gardiner 2003, Kirchheiner 2000)
Isolated cases of sedation (in association with other medication) and constipation have been published. (Sinha 2021)
May induce increased plasma levels of Prolactin but less frequently and lower than other antipsychotic drugs. (David 2000, Crawford 1997)
Some expert authors consider the use of olanzapine safe during breastfeeding (Uguz 2021 y 2016, Teodorescu 2020, Rybakowski 2019, Larsen 2015, Parikh 2014, Rowe 2013, Klinger 2013), being the antipsychotic drug of first choice in breastfeeding. (Pacchiarotti 2016)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM